USA - NASDAQ:ACB - CA05156X8504 - Common Stock
The current stock price of ACB is 4.67 USD. In the past month the price decreased by -13.52%. In the past year, price increased by 11.19%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 43.96 | 914.89B | ||
| JNJ | JOHNSON & JOHNSON | 18.15 | 453.76B | ||
| MRK | MERCK & CO. INC. | 9.85 | 216.68B | ||
| PFE | PFIZER INC | 7.62 | 138.67B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.2 | 96.19B | ||
| ZTS | ZOETIS INC | 18.89 | 53.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.48B | ||
| VTRS | VIATRIS INC | 4.36 | 11.86B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.2 | 11.06B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.78 | 7.95B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.88B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.71 | 4.10B |
Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. The company is headquartered in Leduc, Alberta and currently employs 1,101 full-time employees. The company went IPO on 2007-09-26. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The firm's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The firm also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
AURORA CANNABIS INC
2207 90B Street Sw
Leduc ALBERTA T5J 1Y6 CA
CEO: Terry Booth
Employees: 1073
Phone: 16043625207
Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. The company is headquartered in Leduc, Alberta and currently employs 1,101 full-time employees. The company went IPO on 2007-09-26. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The firm's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The firm also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
The current stock price of ACB is 4.67 USD. The price increased by 2.64% in the last trading session.
ACB does not pay a dividend.
ACB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
The Revenue of AURORA CANNABIS INC (ACB) is expected to grow by 8.72% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AURORA CANNABIS INC (ACB) has a market capitalization of 262.69M USD. This makes ACB a Micro Cap stock.
You can find the ownership structure of AURORA CANNABIS INC (ACB) on the Ownership tab.
ChartMill assigns a technical rating of 1 / 10 to ACB. When comparing the yearly performance of all stocks, ACB turns out to be only a medium performer in the overall market: it outperformed 48.35% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ACB. ACB may be in some trouble as it scores bad on both profitability and health.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.32% | ||
| ROE | -3.53% | ||
| Debt/Equity | 0.07 |
9 analysts have analysed ACB and the average price target is 5.76 USD. This implies a price increase of 23.44% is expected in the next year compared to the current price of 4.67.
For the next year, analysts expect an EPS growth of -288.53% and a revenue growth 8.72% for ACB